TAK-733
10mM in DMSO
- Product Code: 239088
CAS:
1035555-63-5
| Molecular Weight: | 504.23 g./mol | Molecular Formula: | C₁₇H₁₅F₂IN₄O₄ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD24386349 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
TAK-733 is a potent and selective inhibitor of MEK1/2 (mitogen-activated protein kinase kinase), which plays a key role in the RAS/RAF/MEK/ERK signaling pathway. This pathway is frequently dysregulated in various cancers, especially those with mutations in BRAF or RAS genes. TAK-733 has been investigated primarily for its antitumor activity in preclinical cancer models.
It has shown efficacy in inhibiting the proliferation of cancer cells by blocking MEK-dependent signaling, leading to cell cycle arrest and apoptosis. Studies have demonstrated its activity against melanoma, non-small cell lung cancer, and colorectal cancer cell lines, particularly those harboring BRAF mutations.
Due to its high selectivity and pharmacokinetic profile, TAK-733 has been used as a research tool to understand MEK inhibition mechanisms and pathway dynamics. Although it did not advance into late-stage clinical trials, it contributed valuable insights into the development of other MEK inhibitors for oncology therapeutics.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | $688.01 |
+
-
|
TAK-733
TAK-733 is a potent and selective inhibitor of MEK1/2 (mitogen-activated protein kinase kinase), which plays a key role in the RAS/RAF/MEK/ERK signaling pathway. This pathway is frequently dysregulated in various cancers, especially those with mutations in BRAF or RAS genes. TAK-733 has been investigated primarily for its antitumor activity in preclinical cancer models.
It has shown efficacy in inhibiting the proliferation of cancer cells by blocking MEK-dependent signaling, leading to cell cycle arrest and apoptosis. Studies have demonstrated its activity against melanoma, non-small cell lung cancer, and colorectal cancer cell lines, particularly those harboring BRAF mutations.
Due to its high selectivity and pharmacokinetic profile, TAK-733 has been used as a research tool to understand MEK inhibition mechanisms and pathway dynamics. Although it did not advance into late-stage clinical trials, it contributed valuable insights into the development of other MEK inhibitors for oncology therapeutics.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
$0.00
$0.00
Total :